Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
|Articles|November 3, 2003
First selective aldosterone-blocker now approved for CHF
Clinicians will soon be able to offer their patients the first aldosterone-receptor blocker to be approved for the treatment of congestive heart failure (CHF). The FDA recently approved eplerenone (Inspra, Pfizer) to improve the survival of stable patients with left ventricular systolic dysfunction and clinical evidence of CHF following an acute myocardial infarction (MI).
Advertisement
Advertisement
Related to this article
Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.
Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.
Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.
Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Generic Drug Costs Burdening Patients as Much as Brand Name Options
3
How the Main Street Pharmacy Access Act Advances Pharmacist Provider Status
4
Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech
5